About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/20/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/20/2021.

High Dose Omega 3 in People at Risk for Dementia

Clinicaltrials.gov identifier NCT03926351

Recruitment Status Recruiting

First Posted April 24, 2019

Last update posted April 24, 2019

Study Description

Brief summary:

The aim of this study is the efficacy of a docosahexaenoic acid (DHA)-rich dietary supplement in improving key dementia-related mechanisms and cognitive function in older people at risk for dementia. This is a randomized placebo-controlled, 24 weeks, phase 2 study of Omega 3 in people with increased risk of dementia. The aim is to explore the effects of DHA on cognitive performance (CERAD 10 word memory tests, TMT A/B, Stroop Color-Word, FAS, VOSP silhouettes, Cantab-test (RT, PAL, SWT)), biological markers (blood: CRP, NLF, TNF-alpha, MCI-1, PBMC Abeta middomain, Omega-3-index, IL, CSF: NLF, sTREM2, Ab 1-42, total and -phospho-tau) and imaging (MRI: standard structural DDI protocol including Freesurfer and WML measurements, DTI and ASL).

  • Condition or Disease:Cognitive Dysfunction
    Pathologic Processes
    Brain Diseases
    SCD
    Dementia
    Inflammation
    Mild Cognitive Impairment
    Cognitive Decline
    Central Nervous System Diseases
    Nervous System Diseases
    Neurocognitive Disorders
    Mental Disorder
    Cognition Disorders
  • Intervention/Treatment: Dietary Supplement: Omega-3 capsules
    Dietary Supplement: Olive oil
  • Phase: Phase 2
Detailed Description

Earlier trials with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been moderately promising, but these interventions often suffered from relatively low DHA concentrations. In this trial, the investigators will use a DHA-rich dietary supplement formulated using a self-microemulsifying delivery system to accelerate absorption. Modification of innate immune activity has already been seen using DHA-rich supplements, and this type of intervention has been shown to ameliorate AD-associated PBMC profiles, and to be associated with improvements in cognition. DHA can cross the BBB, and the resulting CSF concentrations are associated with reduced CSF total tau levels indicating that DHA reduce neurodegeneration, ameliorate Abeta42 induced neuronal damage, and increase microglia Abeta phagocytosis. However, pre-clinical and pre-dementia intervention trials linked to biomarkers for the AD disease process is lacking, and therefore, stratification with respect to stage of disease process has not been performed. Study cohort: subjects in this pilot study will be recruited from the Norwegian Dementia Disease Initiative (DDI) cohort. The DDI cohort consists of 600 participants with Subjective Cognitive Dedcline (SCD), Mild Cognitive Impairment (MCI) and normal control subjects that have been included at dementia centres across Norway during 2012-2016. Blood samples and cerebrospinal fluid (CSF) have been collected and are stored centrally at Ahus. A comprehensive and highly standarized clinical assessment program has been administered by trained raters (assessors). The investigators are currently performing 2-year follow-up evaluations. Genetic data including APOE-isoforms have been collected as have baseline and follow-up MRIs, PET scans (so far in Oslo and Bergen) and baseline CSF examinations (Ab, total-tau and phosphorus-tau). Cognitive assessments at baseline and follow-up include MMSE and Clinical Dementia Rating (CDR), CERAD 10 word memory test, Clock drawing test, Trail Making Test A and B, Verbal fluency test (FAS), visual recognition test (VOSP silhouettes), Stropp Coloraturas-Word. Data is assembled in a customised database (UiO secure server (TSD)), developed based on XNAT (http://www.xnat.org) and also connected to pipelines for image analysis. A selection from CANTAB MCI test battery including RTI (reaction time), PAL (paired associates learning test), and SWM (spatial working memory). Study design: All subjects included in the intervention study will have completed 2-year follow-up in the DDI study prior to inclusion and will be on stable medication at least 3 months prior to baseline examinations. Based on the existing electronic CRF for DDI, social e-RCT-CRFs will be developed and programmed into the proprietary XNAT database. Patients fulfilling the inclusion criteria will be identified by a nurse at the memory outpatient clinics and will be given a short information letter regarding the study. Written consent will be asked for. Thereafter, a medical and neurological examination of the patient will be performed, including a medical history and medication use. This initial pilot study is a minor feasibility study with 40 subjects randomised equally to either of 2 treatment groups for 24 weeks, Omega-3 3 capsules/day Placebo 3 capsules/day Each study participant will take 3 capsules in the morning for the 24-week study period. The study may be followed by a larger and statistical valid study. Patients will be randomized (by means of a computerized program) to identically appearing set of capsules with Omega-3 or placebo, 1:1 (produced by BASF AS). Optional extension study: Participants will be offered another 24-week Omega-3 capsule supply after study end, and a follow-up assessment after 1 year will be conducted, comparing those with and without continuous Omega-3 treatment.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 40 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Intervention Model Description: A randomized, 24-week parallel-group placebo-controlled (Phase 2) pilot-study of high dose Omega 3 (DHA) in people at risk for dementia
  • Masking: Triple (Participant, Care Provider, Investigator)
  • Primary Purpose: Prevention
  • Official Title: A Randomized, 24 Week Parallel-group Placebo-controlled (Phase 2) Pilot-study of High Dose Omega 3 (DHA) in People at Risk for Dementia
  • Actual Study Start Date: October 2018
  • Estimated Primary Completion Date: October 2019
  • Estimated Study Completion Date: October 2020
Arms and interventions
Arm Intervention/treatment
Experimental: Arm 2a; Omega-3 capsules
Valid for the first 24 weeks of the study. Arm 2a; Omega-3, (1000 mg fill weight per capsule) containing omega-3 ethyl ester concentrate with a high proportion of DHA.
Dietary Supplement: Omega-3 capsules
BASF AS is the developer of the gelatine capsules containing Omega-3 ethyl ester from fish oil concentrate, as the dietary (nutritional) ingredient. The additional capsule fill ingredients are food additives permitted in food supplements according to Regulation (EC) No 1333/2008 on Food additives.
Placebo Comparator: Arm 1a; Placebo
Valid for the first 24 weeks of the study. Arm 1a: placebo, soft gelatine capsule containing 1000 mg olive oil, refined.
Dietary Supplement: Olive oil
Soft gelatine capsule containing 1000 mg olive oil, refined.
Outcome Measures
  • Primary Outcome Measures: 1. Cognitive function [ Time Frame: Baseline to 24 weeks ]
    CERAD 10 word memory test relative to placebo
  • Secondary Outcome Measures: 1. Blood PBMC betaAmyloid mid-domain assay [ Time Frame: Baseline to 24 weeks ]
    IVD assay
  • 2. CSF betaAmyloid 1-42 [ Time Frame: Baseline to 24 weeks ]
    IVD assay
  • 3. CSF TAU [ Time Frame: Baseline to 24 weeks ]
    IVD assay
  • 4. CSF Phospho-TAU [ Time Frame: Baseline to 24 weeks ]
    IVD assay
  • 5. MRI ASL [ Time Frame: Baseline to 24 weeks ]
    MRI procedure
  • 6. MRI WML [ Time Frame: Baseline to 24 weeks ]
    MRI procedure
  • 7. MRI DTI [ Time Frame: Baseline to 24 weeks ]
    MRI procedure
  • 8. Cognitive function [ Time Frame: Baseline to 24 weeks ]
    Cantab RT test relative to placebo
  • 9. Cognitive function [ Time Frame: Baseline to 24 weeks ]
    Cantab PAL test relative to placebo
  • 10. Cognitive function [ Time Frame: Baseline to 24 weeks ]
    Cantab SWT test relative to placebo
Eligibility Criteria
  • Ages Eligible for Study: 50 to 79 Years (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- Age > 50 years

- SCD or MCI

- No evidence of neurodegeneration (i.e. CSF phospho and total tau-levels below cut-off)

- Scandinavian mother tongue

- Completed 2-year follow-up in the DDI-study

- Stable medication for at least 3 months prior to baseline exam

Exclusion Criteria:

- Dementia (defined as MMSE /= 1))

- Other dementia giving disease than AD

- Other brain disease

- Significant depression

- Unstable coronary heart disease or heart failure in need of treatment

- Systemic inflammatory diseases

- Somatic disease that might affect cognitive function adversely

- Usage of anticoagulants

- Prior radiation- or chemo-therapy possibly affecting CNS

- Relevant cancer or other serious disease with expected survival < 5 years - Fish meal intake more than 2 times a week - Regularly intake of Omega-3 supplements over the last 3 months

Contacts and Locations
Contacts

Contact: Tormod Fladby, MD PhD +4792817764 tormod.fladby@medisin.uio.no

Contact: Erik Christensen, MD PhD +4795939918 erik@pre-diagnostics.com

Locations

Norway
Akershus university hospital, Sykehusveien 25
Lørenskog

Sponsors and Collaborators

University Hospital, Akershus

BASF AS

Pre Diagnostics AS

Investigators

Principal Investigator: Tormod Fladby, MD PhD University Hospital, Akershus

More Information
  • Responsible Party: University Hospital, Akershus
  • ClinicalTrials.gov Identifier: NCT03926351 History of Changes
  • Other Study ID Numbers: REC: 2017/1364
  • First Posted: April 24, 2019 Key Record Dates
  • Last Update Posted: April 24, 2019
  • Last Verified: April 2019
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Dementia
    Brain Diseases
    Central Nervous System Diseases
    Disease
    Inflammation
    Pathologic Processes
    Cognitive Dysfunction
    Mental Disorders
    Neurocognitive Disorders
    Cognition Disorders
    Nervous System Diseases